Elicio Therapeutics (ELTX) Long-Term Investments (2020 - 2023)

Elicio Therapeutics has reported Long-Term Investments for 4 years, with the latest figure at $150000.0 in Q1 2023.

• For the quarter ending Q1 2023, Long-Term Investments fell 79.51% year-over-year to $150000.0; the trailing twelve-month figure through Mar 2023 stood at $150000.0 (down 79.51% YoY), and the FY2022 full-year result was $874000.0, up 20.89% from the prior year.
• Long-Term Investments for Q1 2023 stood at $150000.0, down from $874000.0 in the prior quarter.
• The five-year high for Long-Term Investments was $877000.0 in Q1 2021, with the low at $150000.0 in Q1 2023.
• Historically, Long-Term Investments has averaged $762200.0 across 4 years, with a median of $852500.0 in 2021.
• Annual changes were most pronounced in 2022 — Long-Term Investments rose 20.89% — and 2023, when it slumped 79.51%.
• Elicio Therapeutics' Long-Term Investments stood at $822000.0 in 2020, then retreated by 12.04% to $723000.0 in 2021, then rose by 20.89% to $874000.0 in 2022, then sank by 82.84% to $150000.0 in 2023.
• The last three Long-Term Investments figures came in at $150000.0 (Q1 2023), $874000.0 (Q4 2022), and $874000.0 (Q3 2022), per Business Quant data.